SC13: MICROFLUIDICS AND LAB-ON-A-CHIP DEVICES FOR POCT: TECHNOLOGIES AND COMMERCIALIZATION
Room Location: 154

Sunday, March 10 | 5:30 - 8:30 PM

ABOUT THIS COURSE:

This short course will provide an overview of microfluidic techniques, including valved and valve-less devices, pumped systems, and capillary flow approaches. Practical examples will keep the discussion grounded in the realization of commercializable devices. We will discuss engineering approaches to enhance the advantages and minimize the challenges. Throughout, the science will be linked to the commercial case for these devices, including a full discussion of a recent success story of a centrifugal microfluidic molecular assay system.

COURSE AGENDA:

5:30 Introductions and Course Begins

6:15 Dinner Buffet

6:45 Course Resumes

8:30 Course Ends

INSTRUCTORS:

Kris Buchanan, CEO and Founder, Phase Three Product Development

Kris Buchanan is the owner and CEO of Phase Three Product Development which was founded in 2009. He has driven the development of many products while holding numerous engineering and product development positions in companies which produce products from consumer electronics to medical devices. After graduating with a Mechanical Engineering degree from Rose-Hulman Institute of Technology, Mr. Buchanan worked as a young engineer in the computer hard disc drive industry in the 1980’s.  He learned extensively about designing and manufacturing high volume/low profit margin products. Mr. Buchanan has been awarded over 75 USPTO and international patents as inventor or co-inventor. These patents range from air filtration and spin motor design in the disc drive industry to bio containment, nozzle and flow cell designs for flow cytometry to patents in the microfluidics field. More recently, Mr. Buchanan has helped researchers develop designs and systems which allow “organ-on-chip” technologies to be developed and to prepare them for commercialization while also developing lab-on-a-chip technologies for continuous cell sorting. Phase Three has been instrumental in preparing microfluidics products for integration in water quality and food safety applications which cover cellular therapy, RNA detection, cellular analysis, and protein detection fields. 

Evan F Cromwell, President & CEO, Protein Fluidics

Evan is the founder, President and CEO of Protein Fluidics, Inc. Protein Fluidics provides protein analysis and immunoassay systems using microfluidics to accelerate data driven decisions in the laboratory. He has over 30 years of senior executive and technical expertise in numerous hi-tech industries including hard disk drive, semiconductor, telecom, and biotechnology. He has been involved in all phases of the design, development, and manufacture of systems for biological assays, materials analysis, optical inspection, and process control. Prior to Protein Fluidic, Evan served as the President and CEO of Blueshift Biotechnologies, a high-content screening and analysis venture that was acquired by Molecular Devices, a Danaher company, in 2008. At Molecular Devices, Evan led global technology development initiatives for novel Life Sciences products, directed an assay development group, and chaired the company’s scientific advisory board. Evan’s passion is integrating new technologies into products that provide unexpected value to customers in life sciences and other communities. Evan holds a B.S. in Chemistry from Caltech and earned his Ph.D. in Physical Chemistry at the University of California, Berkeley. He has authored 40+ publications in the fields of biology, physical chemistry, and optical instrumentation and holds 16 patents

Chris Myatt, Founder & CEO, MBio Diagnostics, Inc.

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies. He earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. Chris also earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

Viktor Shkolnikov, PhD, HP Labs, Microfluidics  

Viktor Shkolnikov at HP labs leads a team of scientists and engineers to develop novel microfluidic and electrokinetic technology for solving valuable diagnostics problems, such as minimally invasive diagnosis of cancer (a project he conceived and initiated). His interests and expertise lie at the interface between medicine and fluid mechanics (and the associated physics, chemistry, and engineering) and he constantly seeks ways of how these can be leveraged to alleviate pain and improve health. He is also the author of “Principles of Microfluidics,” a fundamental text in the field. Viktor Shkolnikov received his Ph.D., M.S., and B.S. all in Mechanical Engineering and all from Stanford University.

Richard Spero, PhD, Co-founder, CEO, Redbud Labs

Richard Spero is co-founder and CEO of Redbud Labs, and co-inventor of Redbud’s biomimetic cilia technology. Trained as a physicist and systems engineer, Dr. Spero has contributed to the discovery of novel methods for fluid processing at the microscale, including pumping, mixing, cell sorting, and analyte isolation. Prior to founding Redbud Labs, Dr. Spero earned his PhD in Physics at the University of North Carolina at Chapel Hill, where he studied blood clot rheology and developed novel systems for magnetic manipulation and time-dependent high content screening

Back To Short Courses